Takeda Pharmaceutical Company Limited
) and its subsidiary Millennium, recently decided to stop its
ganitumab phase III (GAMMA) global trial in Japan. Takeda's
decision was based on
) decision to stop the global trial with the oncology
As per the 2008 agreement with Amgen, Takeda is responsible to
commercialize and develop 12 molecules from Amgen's portfolio which
included the oncology candidate ganitumab.
We note that Amgen recently suffered a pipeline setback for its
oncology candidate, ganitumab. The randomized, multicenter,
double-blind, GAMMA study evaluated whether the combination of
) Gemzar improved overall survival in patients suffering from
metastatic adenocarcinoma of the pancreas versus placebo and
Gemzar, as a first-line therapy.
However, after conducting a pre-planned interim analysis of the
data, an independent Data Monitoring Committee (DMC) concluded that
the combination of AMG479 and Gemzar would not be likely to improve
survival in patients compared to Gemzar plus placebo. However, the
DMC's analysis of the data from the phase III study did not raise
any safety concern(s).
Takeda and Millennium will discuss the future of the candidate
Takeda is one of the largest pharmaceutical companies in Japan
and one of the worldwide leaders in the industry. We believe the
halting of the ganitumab study will not be a major concern for
Takeda. We expect investor focus to stay on the company's marketed
products and the success of other late-stage candidates.
Takeda carries a Zacks #3 Rank (Hold rating) in the short
AMGEN INC (AMGN): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis
(TKPYY): ETF Research Reports
To read this article on Zacks.com click here.